The enzyme dipeptidyl peptidase-4 (DPP-4) prevents the inactivation of glucagon-like peptide-1 (GLP-1). Since GLP-1-based therapy is a promising novel treatment of type 2 diabetes, the strategy to ...

A total of 20,146 patients with nephrolithiasis and type 2 diabetes, including those with gout at baseline, initiated an SGLT ...

The following is a summary of “Sodium-glucose cotransporter 2 inhibitors and glaucoma in patients with type 2 diabetes,” ...

Alogliptin (NESINA), a dipeptidyl peptidase IV (DPP-4) inhibitor, was approved by the FDA on January 25, 2013 to improve blood sugar control in adults with type 2 diabetes. This drug had been ...

They compared patients prescribed semaglutide—a glucagon-like peptide-1 (GLP-1) receptor agonist—to those prescribed one of seven other anti-diabetic drugs, including metformin, dipeptidyl ...

Mizuho Securities analyst Graig Suvannavejh has maintained their bullish stance on INSM stock, giving a Buy rating on November 5. Graig ...

Grapefruit can interact with many medications, potentially affecting the way they work or increasing side effects. Some of ...

Egypt: A recent randomized controlled trial has demonstrated that sitagliptin, a DPP-4 inhibitor, significantly improves ...

"In the emulated clinical trial, the use of SGLT2 inhibitors compared to DPP4 inhibits was linked to significantly lower ...

In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Insmed (INSM – Research Report), with a price ...

Semaglutide, the active ingredient in the diabetes and weight loss drugs Ozempic and Wegovy, could lower the risk for ...